A.R.T. Advisors’s Arcus Biosciences RCUS Stock Holding History

A.R.T. Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,401	Closed	-$167K	–	1646
2019 Q3	$167K	Buy	+18,401	New	+$148K	0.01%	1207

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's RCUS Position: Q4 2019 in Review

A.R.T. Advisors sold out of Arcus Biosciences (RCUS) in Q4 2019, closing a stake of 18,401 shares — an estimated $167K sold.

A.R.T. Advisors first reported a position in RCUS in Q3 2019 and held it in 1 quarter. The position peaked at $167K in Q3 2019. 75 funds tracked by Wall St. Rank hold RCUS as of Q4 2019.

A.R.T. Advisors reported no remaining Arcus Biosciences position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 18,401 Arcus Biosciences shares in Q4 2019, an estimated $167K.
A.R.T. Advisors first reported a position in Arcus Biosciences in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Arcus Biosciences position peaked at $167K in Q3 2019.
75 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.